Low bone-mineral density in patients with HIV: Pathogenesis and clinical significance

Current Opinion in Endocrinology and Diabetes

Volumn 13, Issue 6, 2006, Pages 497-502

  Yin, Michael T ^a   Shane, Elizabeth ^a,b  

^a College of Physicians and Surgeons ^*  (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

HIV; Low bone mineral density; Metabolic complications; Osteoporosis

Indexed keywords

ALENDRONIC ACID; AMPRENAVIR; ANTIRETROVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; EFAVIRENZ; IBANDRONIC ACID; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PARATHYROID HORMONE[1-34]; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STAVUDINE; TENOFOVIR; VITAMIN D;

AGING; ANTHROPOMETRY; BONE DENSITY; BONE METABOLISM; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; FOLLOW UP; FRAGILITY FRACTURE; HORMONAL REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; REGULATORY MECHANISM; REVIEW; SURVIVAL;

EID: 33750612582     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3280109b6c     Document Type: Review

References (70)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785-795.
2. Fairfield WP, Finkelstein JS, Klibanski A, et al. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab 2001; 86:2020-2026.
3. Fairfield WP, Treat M, Rosenthal DI, et al. Effects of testosterone and exercise on muscle leanness in eugonadal men with AIDS wasting. J Appl Physiol 2001; 90:2166-2171.
4. Huang JS, Wilkie SJ, Sullivan MP, et al. Reduced bone density in androgen-deficient women with acquired immune deficiency syndrome wasting. J Clin Endocrinol Metab 2001; 86:3533-3539.
5. Arnsten JH, Freeman R, Howard AA, et al. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis 2006; 42:1014-1020. A large cross-sectional study of BMD in HIV-infected women with well matched controls.
6. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38:263-270.
7. Nolan D, Upton R, McKinnon E, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001; 15:1275-1280.
8. Tsekes G, Chrysos G, Douskas G, et al. Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors. HIV Med 2002; 3:85-90.
9. Dube MP, Qian D, Edmondson-Melancon H, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002; 35:475-481.
10. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in HIV-infected women. J Clin Endocrinol Metab 2006; 91:2938-2945. [Epub ahead of print]. The only published longitudinal study of BMD in HIV-infected women.
11. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36:482-490.
12. Hernandez Quero J, Ortego Centeno N, Munoz-Torres M, et al. Alterations in bone turnover in HIV-positive patients. Infection 1993; 21:220-222.
13. Paton NI, Macallan DC, Griffin GE, et al. Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 1997; 61:30-32.
14. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy [see comments]. AIDS 2000; 14:F63-F67.
15. McDermott AY, Shevitz A, Knox T, et al. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr 2001; 74:679-686.
16. Carr A, Miller J, Eisman JA, et al. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight preantiretroviral therapy. AIDS 2001; 15:703-709.
17. Brown T, Ruppe M, Kassner R, et al. Reduced bone mineral density in HIV infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 2004; 89:1200-1206.
18. Moore AL, Vashisht A, Sabin CA, et al. Reduced bone mineral density in HIV-positive individuals. AIDS 2001; 15:1731-1733.
19. Teichmann J, Stephan E, Lange U, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect 2003; 46:221-227.
20. Dolan SE, Huang JS, Killilea KM, et al. Reduced bone density in HIV-infected women. AIDS 2004; 18:475-483.
21. Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 2005; 16:1345-1352.
22. Mallon PW, Miller J, Cooper DA, et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17:971-979.
23. Guaraldi G, Ventura P, Albuzza M, et al. Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. AIDS 2001; 15:137-138.
24. Stephens EA, Das R, Madge S, et al. Symptomatic osteoporosis in two young HIV-positive African women. AIDS 1999; 13:2605-2606.
25. McComsey GA, Huang JS, Woolley IJ, et al. Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management. J Int Assoc Physicians AIDS Care (Chic Ill) 2004; 3:86-91.
26. Canque B, Marandin A, Rosenzwajg M, et al. Susceptibility of human bone marrow stromal cells to human immunodeficiency virus (HIV). Virology 1995; 208:779-783.
27. Serrano S, Marinoso ML, Soriano JC, et al. Bone remodelling in human immunodeficiency virus-1-infected patients: a histomorphometric study. Bone 1995; 16:185-191.
28. Toneguzzi S, Lisignoli G, Monaco MC, et al. Osteoblastic cell lines are not susceptible to HIV infection. Boll Soc Ital Biol Sper 1995; 71:275-279.
29. Lahdevirta J, Maury CP, Teppo AM, et al. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988; 85:289-291.
30. Breen EC, Rezai AR, Nakajima K, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 1990; 144:480-484.
31. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332:305-311.
32. Alsina M, Guise TA, Roodman GD. Cytokine regulation of bone cell differentiation. Vitam Horm 1996; 52:63-98.
33. Roodman GD. Role of cytokines in the regulation of bone resorption. Calcif Tissue Int 1993; 53 (Suppl 1):S94-S98.
34. Armstrong AP, Tometsko ME, Glaccum M, et al. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 2002; 277:44347-44356.
35. Manolagas SC, Bellido T, Jilka RL. New insights into the cellular, biochemical, and molecular basis of postmenopausal and senile osteoporosis: roles of IL-6 and gp130. Int J Immunopharmacol 1995; 17:109-116.
36. Fakruddin JM, Laurence J. HIV envelope gp 120-mediated regulation of osteoclastogenesis via RANKL secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 2003; 278:48251-48258.
37. Mellert W, Kleinschmidt A, Schmidt J, et al. Infection of human fibroblasts and osteoblast-like cells with HIV-1. AIDS 1990; 4:527-535.
38. Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999; 84:145-150.
39. Teichmann J, Stephan E, Discher T, et al. Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiency virus infection. Metab Clin Exp 2000; 49:1134-1139.
40. McNurlan MA, Garlick PJ, Frost RA, et al. Albumin synthesis and bone collagen formation in human immunodeficiency virus-positive subjects: differential effects of growth hormone administration. J Clin Endocrinol Metab 1998; 83:3050-3055.
41. Garnero P, Jouvenne P, Buchs N, et al. Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products. Bone 1999; 24:381-385.
42. Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 2003; 15:454-457.
43. Callander NS, Roodman GD. Myeloma bone disease. Semin Hematol 2001; 38:276-285.
44. Jain RG, Lenhard JM. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem 2002; 277:19247-19250.
45. Wang MWH, Wei S, Faccio R, et al. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest 2004; 114:206-213.
46. Zamboni G, Antoniazzi F, Bertoldo F, et al. Altered bone metabolism in children infected with human immunodeficiency virus. Acta Paediatr 2003; 92:12-16.
47. Konishi M, Takahashi K, Yoshimoto E, et al. Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients. AIDS 2005; 19:1240-1241.
48. Rosenthall L, Falutz J. Bone mineral changes in AIDS associated lipodystrophy [abstract]. J Bone Miner Res 2003; 18 (Suppl):278.
49. Gold J, Pocock N, Li Y, et al. Bone mineral density abnormalities in patients with HIV infection. J Acquir Immune Defic Syndr 2002; 30:131-132.
50. Kuhne CA, Heufelder AE, Hofbauer LC. Bone and mineral metabolism in human immunodeficiency virus infection. J Bone Miner Res 2001; 16:2-9.
51. Welch K, Finkbeiner W, Alpers CE, et al. Autopsy findings in the acquired immune deficiency syndrome. JAMA 1984; 252:1152-1159.
52. Hellman P, Albert J, Gidlund M, et al. Impaired parathyroid hormone release in human immunodeficiency virus infection. AIDS Res Hum Retroviruses 1994; 10:391-394.
53. Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS [comment]. Ann Intern Med 1991; 115:665-673.
54. Wharton JM, Coleman DL, Wofsy CB, et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective randomized trial. Ann Intern Med 1986; 105:37-44.
55. Bruera D, Luna N, David DO, et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003; 17:1917-1923.
56. Haug CJ, Aukrust P, Haug E, et al. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 1998; 83:3832-3838.
57. Kuehn EW, Anders HJ, Bogner JR, et al. Hypocalcaemia in HIV infection and AIDS. J Intern Med 1999; 245:69-73.
58. Cozzolino M, Vidal M, Arcidiacono MV, et al. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003; 17:513-520.
59. Honour JW, Schneider MA, Miller RF. Low adrenal androgens in men with HIV infection and the acquired immunodeficiency syndrome. Horm Res 1995; 44:35-39.
60. Christeff N, Gharakhanian S, Thobie N, et al. Evidence for changes in adrenal and testicular steroids during HIV infection. J Acquir Immune Defic Syndr 1992; 5:841-846.
61. Huang JS, Rietschel P, Hadigan CM, et al. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 2001; 15:975-982.
62. Clark RA, Mulligan K, Stamenovic E, et al. Frequency of anovulation and early menopause among women enrolled in selected adult AIDS Clinical Trials Group studies. J Infect Dis 2001; 184:1325-1327.
63. Grinspoon S, Corcoran C, Miller K, et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting [erratum appears in J Clin Endocrinol Metab 1997, 82:3360]. J Clin Endocrinol Metab 1997; 82:1332-1337.
64. Manolagas SC. Role of cytokines in bone resorption. Bone 1995; 17(2 Suppl):63S-67S.
65. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11:1043-1051.
66. Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003; 111:1221-1230.
67. Hofbauer LC, Khosla S, Dunstan CR, et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999; 140:4367-4370.
68. Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials 2004; 5:269-277.
69. Mondy K, Powderly WG, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005; 38:426-431. A controlled study demonstrating short-term increase in BMD and tolerability of alendronate in HIV-infected individuals.
70. Negredo E, Martinez-Lopez E, Paredes R, et al. Reversal of HIV-1 associated osteopenia with once-weekly alendronate. AIDS 2005; 19:243-245.